Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which radiotherapy technique offers best value for pelvic cancers?

NCT ID NCT01325961

Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial compares three modern radiotherapy techniques—helical tomotherapy and two types of dynamic arc therapy (RapidArc and VMAT)—for treating prostate, cervical, and anal canal cancers that require pelvic lymph node irradiation. The goal is to determine which method is most cost-effective while maintaining treatment quality. The study includes 215 adults with locally advanced cancers who need radiation to the pelvic lymph nodes, often alongside chemotherapy or hormone therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (IMRT via helical tomotherapy or dynamic arc therapy)
What this could lead to
If successful, this could identify the most cost-effective radiotherapy technique for treating pelvic cancers, potentially improving access and reducing healthcare costs.
What could go wrong
This is a cost-comparison study, not a test of new treatments. It may not show differences in cancer outcomes or side effects between the techniques.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

215 people

The number who actually took part.

Started

Mar 2011

Finished

Feb 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * WHO performance index ≤ 2 * Age \> 18 years * Histologically confirmed carcinoma * Locally advanced anal canal cancer (\> 4 cm and/or N1 to N3), requiring irradiation of inguinal and pelvic lymph nodes with concomitant chemotherapy * Prostate cancer requiring pelvic lymph node irradiation and hormone therapy * Cervical cancer requiring irradiation of the pelvic lymph nodes, the primary tumor, and parametria with concomitant chemotherapy. Surgical resection may be performed after chemoradiotherapy depending on each center's practices. Boosts via external beam radiotherapy or brachytherapy are accepted * The investigator must ensure that the patient has not expressed its opposition to participate in this study. The signing of a consent form is optional; Exclusion Criteria: * History of invasive cancer (except basal cell carcinoma) * Indication for re-irradiation * Lombo-aortic lymph node irradiation * Postoperative radiotherapy * Geographic distance likely to interfere with patient follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal canal cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anal canal cancer cervical cancer cervical carcinoma prostate cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal canal cancers Cervix cancer Prostate cancer

Contacts and locations

Locations

  • Assistance publique des Hôpitaux de Marseille

    Marseille, 13385, France

  • Centre Alexis Vautrin

    Nancy, 54500, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Centre Val d'Aurelle

    Montpellier, 34298, France

  • Groupe Oncorad

    Montauban, 82000, France

  • Groupe Oncorad

    Toulouse, 31300, France

  • Hôpital Clinique Claude Bernard

    Metz, 57 070, France

  • Hôpital Européen Georges Pompidou

    Paris, Paris, 75015, France

  • Institut Bergonié

    Bordeaux, 33000, France

  • Institut Claudius Regaud

    Toulouse, 31000, France

  • Institut Curie

    Paris, 75013, France

  • Institut Paoli Calmette

    Marseille, 13273, France

  • Institut Sainte Catherine

    Avignon, 84000, France

  • Institut de cancérologie de l'ouest

    Saint-Herblain, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.